Barclays’s ADMA Biologics ADMA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $1.3M | Sell |
143,862
-505,238
| -78% | -$7.97M | ﹤0.01% | 2590 |
|
|
2025
Q4 | $11.8M | Sell |
649,100
-114,846
| -15% | -$1.94M | ﹤0.01% | 1565 |
|
|
2025
Q3 | $11.2M | Sell |
763,946
-34,774
| -4% | -$596K | ﹤0.01% | 1578 |
|
|
2025
Q2 | $14.5M | Buy |
798,720
+352,837
| +79% | +$7.19M | ﹤0.01% | 1312 |
|
|
2025
Q1 | $8.85M | Sell |
445,883
-95,210
| -18% | -$1.65M | ﹤0.01% | 1492 |
|
|
2024
Q4 | $9.28M | Buy |
541,093
+12,464
| +2% | +$234K | ﹤0.01% | 1628 |
|
|
2024
Q3 | $10.6M | Buy |
528,629
+347,692
| +192% | +$5.41M | ﹤0.01% | 1450 |
|
|
2024
Q2 | $2.02M | Sell |
180,937
-93,112
| -34% | -$781K | ﹤0.01% | 2135 |
|
|
2024
Q1 | $1.81M | Sell |
274,049
-306,689
| -53% | -$1.68M | ﹤0.01% | 2655 |
|
|
2023
Q4 | $2.62M | Buy |
580,738
+178,201
| +44% | +$659K | ﹤0.01% | 2690 |
|
|
2023
Q3 | $1.44M | Sell |
402,537
-10,544
| -3% | -$40.6K | ﹤0.01% | 2096 |
|
|
2023
Q2 | $1.52M | Sell |
413,081
-15,968
| -4% | -$59.2K | ﹤0.01% | 2061 |
|
|
2023
Q1 | $1.42M | Sell |
429,049
-35,718
| -8% | -$123K | ﹤0.01% | 2468 |
|
|
2022
Q4 | $1.8M | Sell |
464,767
-3,949
| -0.8% | -$12.2K | ﹤0.01% | 2328 |
|
|
2022
Q3 | $1.14M | Buy |
468,716
+356,293
| +317% | +$855K | ﹤0.01% | 2137 |
|
|
2022
Q2 | $222K | Sell |
112,423
-4,815
| -4% | -$9.47K | ﹤0.01% | 3367 |
|
|
2022
Q1 | $215K | Hold |
117,238
| – | – | ﹤0.01% | 3371 |
|
|
2021
Q4 | $165K | Sell |
117,238
-11,714
| -9% | -$15.4K | ﹤0.01% | 3621 |
|
|
2021
Q3 | $145K | Sell |
128,952
-328,795
| -72% | -$461K | ﹤0.01% | 3760 |
|
|
2021
Q2 | $733K | Buy |
457,747
+285,322
| +165% | +$502K | ﹤0.01% | 2848 |
|
|
2021
Q1 | $303K | Buy |
172,425
+172,339
| +200,394% | +$394K | ﹤0.01% | 3492 |
|
|
2020
Q4 | $0 | Sell |
86
-27,750
| -100% | -$58.3K | ﹤0.01% | 4848 |
|
|
2020
Q3 | $66K | Sell |
27,836
-8,191
| -23% | -$22.5K | ﹤0.01% | 4462 |
|
|
2020
Q2 | $106K | Buy |
36,027
+12,727
| +55% | +$36.6K | ﹤0.01% | 4474 |
|
|
2020
Q1 | $67K | Sell |
23,300
-51,400
| -69% | -$178K | ﹤0.01% | 5036 |
|
|
2019
Q4 | $298K | Sell |
74,700
-353,887
| -83% | -$1.54M | ﹤0.01% | 4735 |
|
|
2019
Q3 | $1.91M | Buy |
428,587
+410,962
| +2,332% | +$1.72M | ﹤0.01% | 2928 |
|
|
2019
Q2 | $68K | Sell |
17,625
-37,842
| -68% | -$167K | ﹤0.01% | 5939 |
|
|
2019
Q1 | $211K | Buy |
55,467
+55,246
| +24,998% | +$195K | ﹤0.01% | 4783 |
|
|
2018
Q4 | $1K | Sell |
221
-7,031
| -97% | -$34.8K | ﹤0.01% | 6773 |
|
|
2018
Q3 | $45K | Buy |
7,252
+5,864
| +422% | +$33.8K | ﹤0.01% | 6140 |
|
|
2018
Q2 | $6K | Sell |
1,388
-1,513
| -52% | -$7.54K | ﹤0.01% | 6659 |
|
|
2018
Q1 | $13K | Buy |
+2,901
| New | +$11.5K | ﹤0.01% | 6572 |
|
Other funds holding ADMA
VCM
VPM
N
Barclays's ADMA Position: Q1 2026 in Review
Barclays reduced its ADMA Biologics (ADMA) stake by 78% in Q1 2026, selling an estimated $7.97M and leaving 143,862 shares worth $1.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2590.
Barclays first reported a position in ADMA in Q1 2018 and has held it in 33 quarters since. The position peaked at $14.5M in Q2 2025. 356 funds tracked by Wall St. Rank hold ADMA as of Q1 2026.
- Barclays held 143,862 shares of ADMA Biologics worth $1.3M as of Q1 2026.
- Barclays sold 505,238 ADMA Biologics shares in Q1 2026, an estimated $7.97M.
- ADMA Biologics made up ﹤0.01% of Barclays's portfolio in Q1 2026, its #2590 holding.
- Barclays first reported a position in ADMA Biologics in Q1 2018 and has held it in 33 quarters since.
- Barclays's ADMA Biologics position peaked at $14.5M in Q2 2025.
- 356 funds tracked by Wall St. Rank held ADMA Biologics as of Q1 2026.
Based on Barclays's 13F filing for Q1 2026, filed 15 May 2026.